{"id":"W2126565162","doi":"10.1093/annonc/mdm554","title":"A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer","year":2007,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":false,"ca_institutions":"Ontario Institute for Cancer Research; Queen's University; University Health Network; Hamilton Health Sciences; Juravinski Cancer Centre; CancerCare Manitoba; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Medicine; Sorafenib; Prostate cancer; Internal medicine; Prostate-specific antigen; Discontinuation; Oncology; Clinical endpoint; Adverse effect; Urology; Cancer; Clinical trial; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003124861,0.0001009277,0.0003831017,0.0001867449,0.00003366198,0.000001553292,0.00005297253,0.00005842869,0.00005186332],"category_scores_gemma":[0.00002768948,0.0000698022,0.00002853491,0.0002975793,0.0001218605,0.00005284887,0.00002859989,0.0001207869,7.917369e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009361681,"about_ca_system_score_gemma":0.0004671826,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007754576,"about_ca_topic_score_gemma":0.001667361,"domain_scores_codex":[0.9988759,0.00003728095,0.0003569917,0.0001798046,0.0002758331,0.0002742366],"domain_scores_gemma":[0.9990375,0.00005034635,0.0001795778,0.0001440528,0.0005017542,0.00008676184],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.07694255,0.05498474,0.7348282,0.0001957219,0.0005437662,0.0003918837,0.01574274,0.00001587034,0.008296926,0.00002561122,0.000819547,0.1072124],"study_design_scores_gemma":[0.0750731,0.1747851,0.7073796,0.0001607825,0.00009592363,0.000001857139,0.003229978,0.000005948654,0.03772786,0.0000343957,0.001377109,0.0001283241],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966936,0.0002564107,7.870996e-7,0.0006687187,0.00003362637,0.001283521,0.0000353187,0.000005579991,0.001022502],"genre_scores_gemma":[0.9993439,0.00008456416,0.00004880994,0.00008440673,0.0000212514,0.0000564605,0.00002965077,0.00001032894,0.0003206017],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1198003,"threshold_uncertainty_score":0.2846451,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08156833559138355,"score_gpt":0.4511618509292627,"score_spread":0.3695935153378792,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}